CureVac N.V.
NASDAQ: CVAC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander Zehnder
- Employees
- 825
- Headquarters
- Tübingen, Germany
- IPO year
- 2020
- Market cap
- $1.0B
- Website
- https://www.curevac.com
Loading CVAC…
Loading profile data…Frequently asked questions about CVAC
What does CureVac N.V. (CVAC) do?
CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase...
Where does CVAC trade?
CureVac N.V. (CVAC) trades on the NASDAQ Global Market.
What sector is CVAC in?
CureVac N.V. (CVAC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CureVac N.V.?
Alexander Zehnder is the chief executive officer of CureVac N.V. (CVAC).
Where is CureVac N.V. headquartered?
CureVac N.V. is headquartered in Germany.
Does CVAC pay a dividend?
CureVac N.V. (CVAC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CVAC go public?
CureVac N.V. (CVAC) completed its initial public offering in 2020.